

Improvement of physical performance in 5/6 nephrectomized CKD model mice through epigenetic modulation of PGC-1 α expression by ghrelin treatment.

Masanori Tamaki^{1,2}, Kazutoshi Miyashita¹, Shu Wakino¹, Masanori Mitsuishi¹, Koichi Hayashi¹, and Hiroshi Itoh¹





1) Department of Internal medicine, School of medicine, Keio University
2) Department of Nephrology, Tokushima University Hospital

52nd ERA-EDTA Congress
London, United Kingdom. 30/05/2015

Introduction

- An improvement of physical performance is expected to bring significant clinical benefits. A physical decline due to chronic kidney disease (CKD) is known to predict a wide range of diseases and morbidity.
- Our recent study revealed that muscle mitochondrial dysfunction could strongly spoil physical performance in 5/6 nephrectomized (5/6Nx) CKD model mice, even when the muscle mass was maintained. (Tamaki et al. *Kidney Int* 2014; 85: 1330-1339).
- Ghrelin, a gastric hormone, is known to have muscle anabolic effect through growth hormone / insulin like growth factor-1 (IGF-1) axis; furthermore, previous reports indicated that ghrelin have beneficial effect for muscle mitochondria.
- Mitochondrial amount is regulated by a representative mitochondrial activator gene, peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 α). Recently, epigenetic modifications of the promoter region in upstream of initiation point of the gene was revealed to critically control the expression.
- The usefulness of ghrelin treatment for a recovery of physical decline was examined by using 5/6Nx CKD model mice, in comparison with IGF-1 treatment, focusing on mitochondria and epigenetic modification of PGC-1 α .


Ghrelin has a possibility to improve physical performance



Methods



- Male C57Bl/6 mice were undergone 5/6 nephrectomy (Heminephrectomy at 6 weeks old and polectomy at 7 weeks old). Ghrelin or IGF-1 (0.3 μ g/gBW; 3 times per week) were administered intraperitoneally, respectively.
- Physical performance (muscle strength and exercise endurance; determined by measuring grip power and running distance, respectively) was examined after the treatment by ghrelin or IGF-1 for a month.
- Skeletal muscle were harvested to evaluate the mitochondrial property.
- Epigenetic regulation of PGC-1 α expression was evaluated by using of PCR analysis. The alteration in the methylation ratio of cytosine residue at 260 base pairs upstream (C-260), a representative methylation site that decrease PGC-1 α expression, was examined by using methylation specific PCR (MSP) and bisulfite genomic sequence (BGS) analysis in the skeletal muscle of mice and ghrelin-treated C2C12 cultured myocytes.

Study design




Results

■ Sham ■ 5/6Nx ■ 5/6Nx + Ghrelin ■ 5/6Nx + IGF-1




[Analysis of the methylation ratio of the promoter region of PGC-1 α gene]


Methylation-specific PCR (MSP) analysis



Bisulfite genomic sequence (BGS) analysis in the skeletal muscle



[Electron microscopy of the gastrocnemius muscle]



Summary and Conclusion

- Ghrelin treatment effectively improved physical decline of 5/6Nx mice through the combined effects to enhance muscle mass and mitochondrial amount, associated with epigenetic modification of muscle PGC-1 α expression.

5/6Nx mice (Young)	Muscle power	Muscle weight	5/6Nx mice (Young)	Exercise endurance	Mitochondrial amount
5/6Nx	No change	No change	5/6Nx	Decreased	Decreased
+ Ghrelin	Increased	Increased	+ Ghrelin	Increased	Increased
+ IGF-1	Increased	Increased	+ IGF-1	Slightly increased	No change

Summary: Muscle insufficiency in CKD model mice and the role of ghrelin

